-- RESEARCH NEWS

Break through Research Early sequencing offers a 67% chance of changing treatments and improved survival.

--
Research from a team led by Brian Piening, PhD, Program Director for Providence Genomics that included colleagues from across Providence as well as collaborators at Illumina and Microsoft demonstrated that a majority (67%) of patients tested with the ProvSeq-Solid Tumor Comprehensive Genomic Profiling (CPG) test were candidates for guideline-recommended precision cancer therapy and those treated with these therapies showed significant improvements in overall survival rate versus chemotherapy.

Research from a team led by Brian Piening, PhD, Program Director for Providence Genomics that included colleagues from across Providence as well as collaborators at Illumina and Microsoft demonstrated that a majority (67%) of patients tested with the ProvSeq-Solid Tumor Comprehensive Genomic Profiling (CPG) test were candidates for guideline-recommended precision cancer therapy and those treated with these therapies showed significant improvements in overall survival rate versus chemotherapy. Read More

Learn more

·       ASCO Daily News

·      Two-thirds of patients with advanced cancer whose biopsies were tested using an in-house comprehensive genomic profiling assay were found to be candidates for precision therapies. Press Release.

·      Providence blog

·       Brian Piening named to new Genomics role

·      Follow Providence Genomics research

 

‍

Find out more
How can we help?
Resources
For Caregivers (our employees)Career OpportunitiesPhysician and Provider CareersProvidence Blog
Our Mission
As expressions of God's healing love, witnessed through the ministry of Jesus, we are steadfast in serving all, especially those who are poor and vulnerable.
Our Values
Compassion, Dignity, Justice, Excellence, Integrity.
Learn more about our mission, vision, and values.
Stay Connected
DisclaimerTerms of Use & Privacy PolicyNotice of Nondiscrimination & Accessibility RightsNotice of Privacy Practices
© 2022 Providence. All rights reserved.